SCHEMBL1715299

SCHEMBL1715299

Cc1cc(OS(=O)(=O)c2ccccc2)no1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
MAPK1 P28482 1/20 0.44
MAOB P27338 2/20 0.42
LMNA P02545 1/20 0.41
GBA1 P04062 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PPIA P62937 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALPL P05186 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALPI P09923 1/20 0.39
ALDH1A1 P00352 2/20 0.38
EDNRB P24530 1/20 0.38
EDNRA P25101 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14367311 0.81 NPC1 (0.41) MAPK1MAOBLMNASMN1; SMN2TDP1
SCHEMBL1714565 0.78 SMN1; SMN2 (0.41) MAOBLMNASMN1; SMN2TDP1MEN1
SCHEMBL11373381 0.76 SMN1; SMN2 (0.40) TSHRMAOBLMNASMN1; SMN2TDP1
SCHEMBL27618647 0.76 SMN1; SMN2 (0.40) MAOBLMNASMN1; SMN2TDP1MEN1
SCHEMBL11359074 0.75 ADAMTS4 (0.36) MAOBSMN1; SMN2TDP1ALPLNPC1
SCHEMBL18180481 0.75 KEAP1 (0.42) TSHRLMNASMN1; SMN2L3MBTL1MEN1
SCHEMBL11360806 0.74 TDP1 (0.35) MAOBLMNASMN1; SMN2TDP1ALPL
SCHEMBL11364194 0.74 NPC1 (0.38) TSHRMAOBLMNASMN1; SMN2TDP1
SCHEMBL11376847 0.73 MAP2K7 (0.39) LMNASMN1; SMN2ALPLMEN1KMT2A
SCHEMBL11359078 0.73 SMN1; SMN2 (0.37) MAOBLMNASMN1; SMN2TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1481966-B1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2011-07-20 EP disclosed
EP-1481966-B1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2011-07-20 EP disclosed
CN-100579957-C Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO LTD 2010-01-13 CN disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
CN-1642906-A Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2005-07-20 CN disclosed
US-20050113424-A1 Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD (JP) 2005-05-26 US disclosed
EP-1481966-A1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113424-A1 Novel arylamidine derivative or salt thereof SLC7A1, NAT1, NACA TSHR 1343/4885MAPK1 71/4885MAOB 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.